New Drug Approved for Irritable Bowel, Chronic Constipation

Linzess sanctioned for cases that don't respond to conventional treatment

THURSDAY, Aug. 30 (HealthDay News) -- Linzess (linaclotide) has been approved by the U.S. Food and Drug Administration to treat forms of chronic constipation that don't respond to traditional treatment, and irritable bowel syndrome (IBS) accompanied by constipation, the agency said Thursday in a news release.

The National Institutes of Health estimate that some 63 million people are affected by chronic constipation, and about 15.3 million have IBS, the FDA said.

Linzess is taken once daily on an empty stomach, at least 30 minutes before the first meal. The most frequently noted adverse reaction is diarrhea.

The drug's label contains a boxed warning that it shouldn't be taken by people aged 16 or younger, the FDA said.

Linzess is produced by Cambridge, Mass.-based Ironwood Pharmaceuticals.

More information

Medline Plus has more about constipation.

Copyright © 2012 HealthDay. All rights reserved.

Powered by

Featured Jobs



Benefits of Membership

FREE E-Newsletters
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues

CESaver
Join our CESaver program to earn up to 100 contact hours for only $34.95
Register Now

Lippincott's NursingCenter.com
Explore a world of online resources

Become a Member